Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Cyclacel Pharma (CYCC) Reports Q4 Loss of $0.62
March 27, 2019 4:10 PM EDTCyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.62), versus ($1.95) reported last year. Revenue for the quarter came in at $150 thousand, versus $0 reported last year.
"We are executing on our targeted oncology strategy with the objective of delivering data readouts from multiple clinical programs, said Spiro Rombotis, President... More
